NanoViricides Inc (NYSE: NNVC) has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients.
What Happened: NanoViricides completed the development of an oral gummies (chewable gel) formulation of NV-CoV-2 for the benefit of symptomatic non-hospitalized patients.
The Company believes that this formulation may have advantages in drug bioavailability over oral pills because of partial sublingual absorption that avoids the gastrointestinal tract.
NanoViricides has previously developed an injectable formulation of NV-CoV-2 that it believes may not require infusion, allowing treatment of severe cases without hospitalization.
NanoViricides has also very recently developed formulations of both NV-CoV-2 and NV-CoV-2-R for direct inhalation into lungs using a nebulizer.
Why It Matters: NV-CoV-2 is non-immunogenic and non-allergenic.
Further, it has not caused hypersensitivity or adverse reactions at injection sites or other adverse events in multiple animal studies.
The candidate was safe and well-tolerated in animal models at very high dosages in single and multiple-dosing studies below the maximum tolerable dose of 1,500 mg/Kg.
The Company has previously demonstrated that NV-CoV-2 was effective in multiple cell culture studies against unrelated coronaviruses.
Price Action: NNVC shares closed at $4.67 on Friday.
Image by Arek Socha from Pixabay
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.